Long-Term Success in the Management of an Extensive Medial Canthal Basal-Cell Carcinoma with Vismodegib
Purpose: To present a case of an extensive basal-cell carcinoma (BCC) of the medial canthus that was successfully treated with vismodegib. The introduction of vismodegib and other Hedgehog pathway inhibitors into clinical practice has provided a new option for the nonsurgical management of periocula...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-07-01
|
| Series: | Journal of Current Ophthalmology |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/joco.joco_76_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849420746779000832 |
|---|---|
| author | Argyrios Tzamalis Georgios Lavasidis Ioannis Tsinopoulos Nikolaos Ziakas |
| author_facet | Argyrios Tzamalis Georgios Lavasidis Ioannis Tsinopoulos Nikolaos Ziakas |
| author_sort | Argyrios Tzamalis |
| collection | DOAJ |
| description | Purpose:
To present a case of an extensive basal-cell carcinoma (BCC) of the medial canthus that was successfully treated with vismodegib. The introduction of vismodegib and other Hedgehog pathway inhibitors into clinical practice has provided a new option for the nonsurgical management of periocular BCC.
Methods:
An 85-year-old male was referred to our clinic with a pigmented nodular BCC but declined any medical intervention. Two years later, the patient returned with an extensive periocular lesion. Through biopsy and magnetic resonance imaging, we confirmed the diagnosis of a nodular-ulcerative BCC extending into the medial orbit. Surgery and radiotherapy were declined. Therefore, oral treatment with vismodegib was initiated.
Results:
After 3 months, complete tumor regression was noted, and the medication was discontinued. The patient remained tumor-free till the last follow-up, 3 years posttreatment. No treatment-related side effects were observed.
Conclusion:
This case demonstrates the clinical value of vismodegib in advanced periocular BCC, particularly when surgery is inappropriate or declined by the patient. |
| format | Article |
| id | doaj-art-c093e49a0ffd45f48870cbf56ec9508c |
| institution | Kabale University |
| issn | 2452-2325 |
| language | English |
| publishDate | 2024-07-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Current Ophthalmology |
| spelling | doaj-art-c093e49a0ffd45f48870cbf56ec9508c2025-08-20T03:31:40ZengWolters Kluwer Medknow PublicationsJournal of Current Ophthalmology2452-23252024-07-0136330030310.4103/joco.joco_76_24Long-Term Success in the Management of an Extensive Medial Canthal Basal-Cell Carcinoma with VismodegibArgyrios TzamalisGeorgios LavasidisIoannis TsinopoulosNikolaos ZiakasPurpose: To present a case of an extensive basal-cell carcinoma (BCC) of the medial canthus that was successfully treated with vismodegib. The introduction of vismodegib and other Hedgehog pathway inhibitors into clinical practice has provided a new option for the nonsurgical management of periocular BCC. Methods: An 85-year-old male was referred to our clinic with a pigmented nodular BCC but declined any medical intervention. Two years later, the patient returned with an extensive periocular lesion. Through biopsy and magnetic resonance imaging, we confirmed the diagnosis of a nodular-ulcerative BCC extending into the medial orbit. Surgery and radiotherapy were declined. Therefore, oral treatment with vismodegib was initiated. Results: After 3 months, complete tumor regression was noted, and the medication was discontinued. The patient remained tumor-free till the last follow-up, 3 years posttreatment. No treatment-related side effects were observed. Conclusion: This case demonstrates the clinical value of vismodegib in advanced periocular BCC, particularly when surgery is inappropriate or declined by the patient.https://journals.lww.com/10.4103/joco.joco_76_24basal-cell carcinomahedgehog pathway inhibitorperiocularvismodegib |
| spellingShingle | Argyrios Tzamalis Georgios Lavasidis Ioannis Tsinopoulos Nikolaos Ziakas Long-Term Success in the Management of an Extensive Medial Canthal Basal-Cell Carcinoma with Vismodegib Journal of Current Ophthalmology basal-cell carcinoma hedgehog pathway inhibitor periocular vismodegib |
| title | Long-Term Success in the Management of an Extensive Medial Canthal Basal-Cell Carcinoma with Vismodegib |
| title_full | Long-Term Success in the Management of an Extensive Medial Canthal Basal-Cell Carcinoma with Vismodegib |
| title_fullStr | Long-Term Success in the Management of an Extensive Medial Canthal Basal-Cell Carcinoma with Vismodegib |
| title_full_unstemmed | Long-Term Success in the Management of an Extensive Medial Canthal Basal-Cell Carcinoma with Vismodegib |
| title_short | Long-Term Success in the Management of an Extensive Medial Canthal Basal-Cell Carcinoma with Vismodegib |
| title_sort | long term success in the management of an extensive medial canthal basal cell carcinoma with vismodegib |
| topic | basal-cell carcinoma hedgehog pathway inhibitor periocular vismodegib |
| url | https://journals.lww.com/10.4103/joco.joco_76_24 |
| work_keys_str_mv | AT argyriostzamalis longtermsuccessinthemanagementofanextensivemedialcanthalbasalcellcarcinomawithvismodegib AT georgioslavasidis longtermsuccessinthemanagementofanextensivemedialcanthalbasalcellcarcinomawithvismodegib AT ioannistsinopoulos longtermsuccessinthemanagementofanextensivemedialcanthalbasalcellcarcinomawithvismodegib AT nikolaosziakas longtermsuccessinthemanagementofanextensivemedialcanthalbasalcellcarcinomawithvismodegib |